A5042685960- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Endometrial and Cervical Cancer Treatments
- Histone Deacetylase Inhibitors Research
- Renal cell carcinoma treatment
- BRCA gene mutations in cancer
- Peptidase Inhibition and Analysis
- Streptococcal Infections and Treatments
- Microbial infections and disease research
- Rabies epidemiology and control
- Neuroendocrine Tumor Research Advances
- Salivary Gland Tumors Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Sarcoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Head and Neck Cancer Studies
- Uterine Myomas and Treatments
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
Institut Gustave Roussy
2023-2024
Sorbonne Université
2019-2023
Pitié-Salpêtrière Hospital
2019-2023
Assistance Publique – Hôpitaux de Paris
2021-2023
Bicêtre Hospital
2021
Université Paris-Saclay
2021
Knowing the homologous recombination deficiency (HRD) status in advanced epithelial ovarian cancer (EOC) is vital for patient management. HRD determined by BRCA1/BRCA2 pathogenic variants or genomic instability. However, tumor DNA analysis inconclusive 15-19% of cases. Peritoneal fluid, available > 95% EOC cases, could serve as an alternative source cell-free (cftDNA) testing. Limited data show feasibility panel gene testing on ascites cfDNA but no study, to date, has investigated testing.We...
5577 Background: HRD testing at diagnosis is crucial for patients with advanced high grade OC (HGOC). status defined by a BRCA1 or BRCA2 pathogenic variant, genomic instability score (GIS). These tests are performed on tumor samples but result in non-contributive 10-19% of cases. We have previously shown that ascites yields quality derived cell-free DNA (cfDNA) suitable testing. Here we present results from an updated prospective series (BRCAm+/-GIS) 20ml peritoneal fluid obtained diagnostic...
5569 Background: Ineov was a phase Ib randomized trial of neoadjuvant carboplatin/paclitaxel (NACT) + durvalumab (D) +/- tremelimumab (T) in unresectable OC. We previously reported safety and encouraging complete resection rates (CC0=70%) pathological response (pCR=18%) at interval debulking surgery (IDS). However there were no significant differences with the addition T to D+NACT. Here we report survival outcomes immune correlates focus on long-term responders. Methods: Pts stage IIIC/IV OC...
5539 Background: Metastatic cervical cancer (mCC) constitutes a global health challenge, despite preventive efforts like HPV vaccination, with imputable 342,000 deaths in 2020. Immunotherapies Immune checkpoint inhibitors (ICI) have been assessed the context of recurrent or mCC. Only 15% patients PDL1+ mCC respond to ICI, however responses can be prolonged. We aimed describe outcomes for long-term responders (LTR) versus non (NLTR) and identify clinico-molecular predictors LTR. Methods:...
<h3>Introduction/Background</h3> Knowledge regarding homologous recombination deficiency (HRD) status at diagnosis is essential to manage patients with advanced epithelial ovarian cancer (EOC). These genomic tests are performed on tumor samples and unfortunately the analysis of DNA missing 15–19% cases. <h3>Methodology</h3> We collected ascites or peritoneal washings (20ml) from 53 undergoing primary secondary laparoscopy for suspicion EOC, therapeutic paracentesis. A Cancer Gene Panel (CGP)...
Abstract Background: Knowledge regarding the homologous recombination deficiency (HRD) status at diagnosis is essential to manage patients (pts) with advanced epithelial ovarian cancer (EOC). HRD defined by either a BRCA1 or BRCA2 mutation, genomic instability (GI). These tests are performed on FFPE tumor samples and unfortunately non-contributive in 12-18% of cases. Advanced OC frequently presents ascites which could provide an alternative source Cell-free DNA (cftDNA). Methods: We...
Small-cell lung cancer (SCLC) accounts for approximately 15% of and is associated with poor prognosis. In platinum-refractory or -resistant SCLC patients, few treatment options are available. Topotecan one the standards care these however, due to its high toxicity, several different approaches employed. FOLFIRI (folinate, 5-fluorouracil irinotecan) a chemotherapy regimen used in digestive neuroendocrine carcinoma, which shares pathological similarities SCLC. this retrospective study, we...
e17587 Background: Metastatic cystic adenoid carcinoma (mCCA) is a rare entity of cancer associated with poor prognostic. Only limited efficacy data based on case-reports and retrospective analysis are available there currently no standard for treatment. The aim our study to evaluate the prognostic factors in recently diagnosed mCCA. Methods: We retrospectively collected demographic from patients treated mCCA between September 2012 January 2019 at Pitié-Salpêtrière Hospital. Univariate was...
Streptobacillus moniliformis, which is transmitted through rodents, an emerging zoonotic pathogen among homeless persons. Untreated, the disease can persist for weeks or months; mortality rate ranges from 7% to 13% and be as high 53% in endocarditis. We report here case of a patient with history chronic subdural hematoma, who suffered rat's bites on his face. He presented our hospital picture cerebral empyema due moniliformis that occurred contiguous spread superinfected skin lesions rat...